Cargando…

Identification of an Activating Mutation in the Extracellular Domain of HER2 Conferring Resistance to Pertuzumab

BACKGROUND: The aberrant expression of HER2 is highly associated with tumour occurrence and metastasis, therefore HER2 is extensively targeted for tumour immunotherapy. For example, trastuzumab and pertuzumab are FDA-approved monoclonal antibodies that target HER2-positive tumour cells. Despite thei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Ying, Wu, Shanshan, Zhuang, Xinlei, Weng, Gaoqi, Fan, Jiansheng, Yang, Xiaoyue, Xu, Yingchun, Pan, Liqiang, Hou, Tingjun, Zhou, Zhan, Chen, Shuqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941612/ https://www.ncbi.nlm.nih.gov/pubmed/31920346 http://dx.doi.org/10.2147/OTT.S232912

Ejemplares similares

A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models
por: Fan, Jiansheng, et al.
Publicado: (2021)

Structure-guided and phage-assisted evolution of a therapeutic anti-EGFR antibody to reverse acquired resistance
por: Zhuang, Xinlei, et al.
Publicado: (2022)

Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain †
por: Cruz, Victor L., et al.
Publicado: (2023)

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis
por: Chen, Shanshan, et al.
Publicado: (2019)

The expanding role of pertuzumab in the treatment of HER2-positive breast cancer
por: Moya-Horno, I, et al.
Publicado: (2015)

The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation
por: Nami, Babak, et al.
Publicado: (2019)

Correction: Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

Pruritus Related to Trastuzumab and Pertuzumab in HER2+ Breast Cancer Patients
por: Gu, Stephanie, et al.
Publicado: (2023)

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2(+) breast cancer in the adaptively randomized I-SPY2 trial
por: Clark, Amy S., et al.
Publicado: (2021)

TCR-mimic antibody-drug conjugates targeting intracellular tumor-specific mutant antigen KRAS G12V mutation
por: Shen, Ying, et al.
Publicado: (2020)

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
por: Bianchini, Giampaolo, et al.
Publicado: (2017)

Neoadjuvant pertuzumab in non-metastatic HER2-positive breast tumors: Multicentric study in Peru (NeoHer)
por: Falcon, Silvia, et al.
Publicado: (2022)

Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab
por: Li, Jie, et al.
Publicado: (2020)

Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
por: Vieira, Cláudia, et al.
Publicado: (2022)

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
por: Dang, Chau, et al.
Publicado: (2022)

Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
por: Nami, Babak, et al.
Publicado: (2018)

A search for synergy in the binding kinetics of Trastuzumab and Pertuzumab whole and F(ab) to Her2
por: Lua, Wai-Heng, et al.
Publicado: (2015)

Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis
por: Alhussein, Muhammad Mustafa, et al.
Publicado: (2021)

HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models
por: Thomas, GaëLle, et al.
Publicado: (2014)

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
por: Yu, Anthony F., et al.
Publicado: (2016)

Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma
por: Yarlagadda, Bhavya, et al.
Publicado: (2019)

Peptide probes derived from pertuzumab by molecular dynamics modeling for HER2 positive tumor imaging
por: Yang, Xiaoliang, et al.
Publicado: (2017)

Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer
por: Liu, Yan-cui, et al.
Publicado: (2019)

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
por: Al Rabadi, Luai S., et al.
Publicado: (2021)

Pertuzumab and Trastuzumab Combination with Concomitant Locoregional Radiotherapy for the Treatment of Breast Cancers with HER2 Receptor Overexpression
por: Aboudaram, Amélie, et al.
Publicado: (2021)

Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
por: Gianni, Luca, et al.
Publicado: (2022)

Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience
por: Hall, Benjamin James, et al.
Publicado: (2022)

Efficacy and safety of treatment with or without pertuzumab for HER2-positive breast cancer: A meta-analysis
por: Chen, Xuan, et al.
Publicado: (2023)

BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
por: Liefaard, M. C., et al.
Publicado: (2023)

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial
por: de Azambuja, E., et al.
Publicado: (2023)

HawkDock: a web server to predict and analyze the protein–protein complex based on computational docking and MM/GBSA
por: Weng, Gaoqi, et al.
Publicado: (2019)

Pertuzumab in Metastatic Breast Cancer
por: Patel, Rachana, et al.
Publicado: (2012)

Effect of VH–VL Families in Pertuzumab and Trastuzumab Recombinant Production, Her2 and FcγIIA Binding
por: Ling, Wei-Li, et al.
Publicado: (2018)

Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results
por: Ocaña, Alberto, et al.
Publicado: (2018)

Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer
por: Kirschbrown, Whitney P., et al.
Publicado: (2019)

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer
por: Collins, Denis, et al.
Publicado: (2017)

Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors
por: Pereira, Patrícia M.R., et al.
Publicado: (2019)

The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world data
por: Borges, Andreia, et al.
Publicado: (2021)

Economic Evaluation of First-Line Pertuzumab Therapy in Patients with HER2-Positive Metastatic Breast Cancer in Japan
por: Moriwaki, Kensuke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7t9r42lr7rjiumca1nu7p7uofm